Hereditary Leiomyomatosis And Renal Cell Cancer

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

FH, CCND1, HIF1A, GABPA, BCL2, BTK, NFE2L2, SDHB, SORD, MME, HSPA4, TNF, SARDH, TP53, VHL, SDS, CDKN1B, SOX11, ACTB, STAT5B, AURKA, SPIB, SPG7, STAT5A, ABL1, XRCC1, BAP1, MED12, NR1I3, TRIM13

FH, CCND1, HIF1A, GABPA, BCL2, BTK, NFE2L2, SDHB, SORD, MME, HSPA4, TNF, SARDH, TP53, VHL, SDS, CDKN1B, SOX11, ACTB, STAT5B, AURKA, SPIB, SPG7, STAT5A, ABL1, XRCC1, BAP1, MED12, NR1I3, TRIM13, CIB1, SMUG1, SETD2, BHD, MALAT1, AURKB, MYC, ROS1, PTPN12, AKT1, ARR3, CASR, CD40, CDKN2B, CCR5, CXADR, EIF4E, EZH2, FOXM1, FUS, HSP90AA1, IGH, IL6, IL10, LDHA, LTA, ACLY, PAX5, PRKAR1A, PTGS2, CXADRP1

Drugs

—

Interested in hearing about new therapies?

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a condition that causes benign tumors of smooth muscle tissue in the skin (cutaneous leiomyomas) and in the uterus in females (uterine leiomyomas, or fibroids). The condition also increases the risk of kidney cancer. Signs and symptoms usually begin in adulthood as skin growths appear on the torso, arms, legs, and occasionally on the face. They tend to increase in size and number over time. About 10% to 16% of people with HLRCC develop a type of kidney cancer called renal cell cancer; symptoms of this cancer may include lower back pain, blood in the urine, and/or a mass in the kidney that can be felt by a physician. Some people have no symptoms until the cancer is advanced. HLRCC is caused by mutations in the FH gene and is inherited in an autosomal dominant manner.